The Bcl-Abl kinase inhibitor imatinib (Gleevec/STI-571) induces killing of Bcr-Abl+ CML through a mechanism that depends on Bim and Bad, but not Bmf or Puma [304, 305, 501]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.